Confidential

Partner & Investor Data Room

Confidential commercial, technical and financial material prepared for prospective institutional partners and investors — the layer we deliberately keep off the public site. Access is provided for evaluation only.

Access gate is for confidentiality acknowledgment · not a security control

Confidential Public sitev2.0 · 2026 · for evaluation

Partner & investor dossier

Beyond the public record — the deal.

The public site proves the science. This room covers what it can't: the pipeline detail, chemistry & manufacturing, regulatory roadmap, economics, deal terms, competitive position and risk — the package a partner or investor needs to act.

The full public evidence record (papers, patents, designations) lives on the site →

01 — Evidence, in one line

The proof, recapped.

The full, sourced record — every paper, patent and designation — is public on the site's Scientific Dossier. Here is the headline; the rest of this room is what's not public.

100+

peer-reviewed papers

27+

patents

2

US FDA orphan designations

25+

years, one team

6

countries

Open the full evidence dossier on the public site

02 — Pipeline detail

All twenty candidates, stage by stage.

Confidential

Each candidate adapts the same magnesium-stabilized antisense chemistry to a different target. Stages are shown honestly; per-candidate data packages are available on request.

CandidateIndicationAreaStageNext milestone
IMM-LIVLiver disease & hepatitis BOncologyClinical evidencePhase III readout (V5 lineage)
IMM-CANSolid tumorsOncologyClinical evidenceTarget expansion
IMM-FIBBenign fibroidsOncologyDiscoveryTarget validation
IMM-TBTuberculosis, incl. MDR-TBInfectiousClinical evidenceOrphan path (V7)
IMM-HSVRecurrent herpes (HSV / VZV)InfectiousDiscoverySequence design
IMM-RESResistant respiratory infectionInfectiousDiscoveryTarget rationale
IMM-SPKPost-viral / spike syndromeInfectiousPreclinicalIn-vivo proof
IMM-METMetabolic / type-2 diabetesMetabolicPreclinicalIND-enabling tox
IMM-CVSBlood-pressure / cardiometabolicMetabolicPreclinicalLead optimization
IMM-KIDKidney diseaseMetabolicPreclinicalTarget validation
IMM-GUTReflux / GI mucosaMetabolicDiscoveryTarget rationale
IMM-BALImmune balanceImmunePreclinicalFormulation
IMM-ASTAsthmaImmunePreclinicalLead optimization
IMM-RHERheumatoid arthritisImmunePreclinicalTarget validation
IMM-PSOPlaque psoriasisImmunePreclinicalFOXP3 / Treg design
IMM-LUPLupus + dermatitisImmunePreclinicalLead optimization
IMM-THYAutoimmune thyroiditisImmuneDiscoveryTarget rationale
IMM-ALZAlzheimer's & neuro-recoveryNeurologyDiscoveryTarget rationale
IMM-PARParkinson's diseaseNeurologyDiscoverySequence design
IMM-DEPMood, anxiety & post-viral fatigueNeurologyDiscoveryTarget rationale

02b — Real-world observations

Twenty anonymized cases, six therapeutic areas.

Confidential

Across the twenty candidate programs, clinicians at IMMUNIC have recorded individual, anonymized outcomes. These are observational, investigational, and not guaranteed — shared here for partner diligence only.

Cardiometabolic

Essential hypertension (with T2DM)Immugence-METoffice SBP −20 mmHg
Type 2 diabetes (uncontrolled)Immugence-METHbA1c −1.2%

Endocrine · Renal · GI

Hashimoto's hypothyroidismImmugence-BALanti-TPO −55%
CKD stage 5 (diabetic nephropathy)Immugence-KIDeGFR +4.6
GERD refractory to PPIImmugence-BALGerdQ −67%

Oncology

Hereditary breast cancer (BRCA1+)Immugence-CAN + BALCTC 0 · CA15-3 −44%
Uterine + ovarian fibroidsImmugence-CAN2 of 3 resolved

Infectious

Chronic hepatitis B (HBeAg+)Immugence-LIVHBV DNA −4.2 log
Recurrent herpes (HSV-1 + VZV)Immugence-BAL + SPKoutbreaks −87%
MDR Pseudomonas / bronchiectasisImmugence-AST + BALsputum sterilized

Autoimmune

SLE + atopic dermatitisImmugence-BALSLEDAI −67%
Rheumatoid arthritis (seropositive)Immugence-BALDAS28 → remission
Plaque psoriasis (mod–severe)Immugence-BALPASI 85

Neurology · Psychiatry

Parkinson's disease (H-Y 2.5)Immugence-PARUPDRS-III −33%
Post-stroke dysphagiaImmugence-ALZ + BALFOIS +4 · 0 pneumonia
MDD + panic (treatment-resistant)Immugence-DEPPHQ-9 −72%
Chronic fatigue (ME/CFS)Immugence-BAL + SPKreturn to work

Other

Bilateral nuclear cataractImmugence-BALVA +4–5 lines
Internal hemorrhoids grade IIIImmugence-BALgrade III → I
Post-COVID-mRNA syndromeImmugence-SPK + BALEF 48 → 58%
Anonymized clinical observations. PDPA-protected · individual results that are not typical, not guaranteed, and not a treatment claim. immugence candidates are investigational and not approved medicines. For partner diligence only.

03 — Chemistry & manufacturing

The Mg-ASO platform, under the hood.

Confidential

The magnesium-chloride matrix is the proprietary core. Process, stability and unit economics are trade secrets shared with serious partners under NDA.

Composition & CMC

Carrier matrixMgCl₂·6H₂O — proprietary, US 2017/0106068 A1
Synthesis routeShared on request
Stability / shelf-lifeShared on request
Scale-up statusShared on request
COGS / unit economicsShared on request
GMP / QC statusShared on request
Supply chainShared on request

PK / PD & safety

Oral bioavailabilityShared on request
BiodistributionShared on request
Half-life / dosingShared on request
Target knockdown (in vivo)Shared on request
Off-target profileShared on request
Tolerability (repeat-dose)Shared on request
Preclinical / investigational. PK/PD and efficacy figures describe research in progress; they are not approved-product claims.

04 — Regulatory roadmap

From Thailand to a global path.

Confidential

Two FDA orphan designations and an operational, Thai-FDA-registered IMMUNIC clinic (not a drug approval) anchor a staged path. Filing timelines are shared with partners.

Now

IMMUNIC clinic operational

Antisense clinical-research center operating in Bangkok — investigational; no drug-approval claims

Near

US FDA orphan track

V5 #457714 granted; V7 DRU-2019-7145 filed — pathway open

Plan

Pre-IND / IND (lead candidate)

Shared on request
Plan

First-in-human (Mg-ASO)

Shared on request
Plan

Global expansion (EMA / others)

Shared on request

05 — Commercial & financials

The numbers and the structure.

Confidential

A US public company has already licensed this lineage at commercial scale (Key Capital, 2020) — the model is de-risked. Round, valuation and projections are provided to qualified parties.

Financials

Funding round / askShared on request
Pre-money valuationShared on request
Use of proceedsShared on request
Revenue to dateShared on request
5-year projectionShared on request
Cap table summaryShared on request

Licensing & deal terms

Licensing fee structureShared on request
Royalty rateShared on request
Territory / exclusivityShared on request
Tech-transfer scopeShared on request
Support packageShared on request
Milestone paymentsShared on request
Not an offer. Nothing in this room is an offer to sell securities or a solicitation; figures are provided for evaluation and discussion only.

06 — Partnership terms

What a Center of Excellence includes.

Confidential

The institutional model in concrete terms — scope, support and economics defined per partner.

You receive

  • Platform license in your area
  • Technology transfer & training
  • Supply & scientific support
  • Co-branded program

You lead

  • Clinical leadership
  • Patient relationship & brand
  • Local regulatory standing

Commercials

Up-front / feesShared on request
Margin / royaltyShared on request
ExclusivityShared on request

07 — Competitive landscape

Where Mg-ASO sits in RNA medicine.

Antisense and siRNA are the proven modalities of the era — every approved player delivers by injection. Oral delivery is the open lane.

PlayerRouteCarrierModality
immugence (Mg-ASO)Oral pillMg²⁺ matrixASO
IonisInjectionGalNAc / nakedASO
AlnylamInjectionGalNAc / LNPsiRNA
AAV gene therapyInjection / IVViral vectorDNA
7–15%

ASO market CAGR

industry estimates

Per-indication market sizingShared on request

Competitor properties from public literature; positioning is immugence's design rationale, not a head-to-head clinical claim.

08 — Risk register

The risks — stated plainly, with mitigations.

Diligence

Serious diligence expects an honest risk view. Here are ours and how we address them.

Clinical translation of Mg-ASO candidates

Builds on the lineage's published Phase II/III oral-immunotherapy results; staged, target-by-target validation.

Regulatory timeline & approval

Two FDA orphan designations already in hand/filed; honest staging — investigational, no approval claims.

“Too good to be true” perception

Evidence-led public site, third-party press (THE STANDARD), and verifiable PMIDs/patents/designations.

Manufacturing scale-up

Simple, scalable magnesium-matrix chemistry vs. complex LNP/AAV; CMC detail in this room.

IP defensibility

27+ patent portfolio incl. composition-of-matter; regional filings EU/JP/CN/AU.

Key-person dependency

Documented inventor + credentialed SAB across Mahidol, UC Davis, Karolinska, DRDC.

09 — Document vault

Source documents, on request.

Confidential

Primary documents behind every claim — released to qualified partners under NDA. (Attach the real files here before sharing.)

Peer-reviewed papers (PDF pack)

10 hero papers

On request

Granted patent documents

6 flagship + portfolio

On request

FDA orphan designation letters

V5 #457714 · V7 filing

On request

BIOTEC / NSTDA lab reports

ASFV · shrimp

On request

Clinical trial protocols

V5 / V7

On request

Corporate & cap-table docs

incorporation · IP assignments

On request

Ready to take this further?

Request the full technical & financial package — CMC, regulatory plan, projections and licensing terms — and a call with the scientific and commercial team.

Request the full packageCenters of Excellence